X
EU regulators back BMS’ Opdivo in new skin cancer use
https://pharmaphorum.com/news/eu-regulators-back-bms-opdivo-in-new-skin-cancer-use/
skin cancer
Incyte shares down sharply after phase 3 skin cancer trial failure
Trial tested epacadostat pill in combination with Merck & Co’s Keytruda
BMS files Opdivo in post-surgery setting
Opdivo performed better than BMS’ Yervoy in clinical trial.
AI on par with dermatologists at diagnosing skin cancer
Technology could inspire a smartphone-based skin cancer diagnostic app.
Roche muscling into melanoma with Tecentriq
Swiss pharma looking to combine immunotherapy with already marketed drugs.
Digital health round-up – skin cancer, vocal biomarkers and more
A round-up of this week’s top digital healthcare news. Marco Ricci reports.
